^
Association details:
| Biomarker: | EGFR C797S |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
New therapeutic approaches to overcoming resistant EGFR exon 20 alterations
Published date:
05/20/2020
Excerpt:
Other alterations, such as EGFR T790 M, are responsive to osimertinib, while the EGFR C797S alteration seen in osimertinib resistance demonstrates preclinical sensitivity to combined brigatinib and cetuximab.
DOI:
10.1016/j.critrevonc.2020.102990
Source:
Title:
Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy
Excerpt:
Our retrospective study provides clinical evidence that combined targeted therapy of brigatinib and cetuximab could provide benefit and may potentially be an effective treatment strategy to improve survival outcomes of patients who acquired EGFR T790M/cis-C797S-mediated resistance to osimertinib.
DOI:
10.1016/j.jtho.2020.04.014
Source:
Title:
Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy
Excerpt:
A 62-year-old woman with no history of smoking came into the clinic with pleural effusion (PE) in May 2013; stage IV lung adenocarcinoma…subsequent first-generation EGFR TKI treatments for EGFR exon 19 deletion…After 8 months of progression-free survival (PFS), the patient experienced development of a new lesion...Genetic testing of circulating tumor DNA from the PE revealed a newly acquired C797S mutation in cis with T790M...A combination of brigatinib (90 mg daily) and cetuximab (600 mg monthly, administered intravenously) has been administered since July 2017 (see Fig. 1A). The patient experienced significant improvement in her fatigue and dyspnea within 1 month...
DOI:
10.1016/j.jtho.2019.01.015
